In one study by Green et al., VWF and ADAMTS13 levels were measured in two groups of patients presenting cardiovascular events; while there were no differences in the concentrations of the molecules between PAD patients and controls, the VWF/ADAMTS13 ratio was higher in patients with peripheral artery disease two months before the acute event, even if the difference was not statistically significant [133]. This evidence concerns the gene VWF and peripheral arterial disease.